项目：

1. 四川大学专职博士后研发基金，2022SCU12027，2022.1.1-2023.12.31，15万元，在研，主持。

文章：

1. Jianhui Zhang, Jiao Li, Kaifeng Hu, Qi Zhou, Xiaoxiao Chen, Jinlei He, Shuangshuang Yin, Yangjian Chi, Xuechun Liao, Yuying Xiao, Hanxiao Qin, Zhiwan Zheng, Jianping Chen. Screening Novel Vaccine Candidates for Leishmania Donovani by Combining Differential Proteomics and Immunoinformatics Analysis, Frontiers in Immunology, 2022, 13: 902066.（共同通讯）

2. Zhiwan Zheng, Jinlei He, Tao Luo, Jianhui Zhang, Qi Zhou, Shuangshuang Yin, Dali Chen, Jie Luo, Jianping Chen, Jiao Li. Mutation Characteristics and Phylogenetic Analysis of Five Leishmania Clinical Isolates, animals, 2022, 12(3): 321.

3. Zhiwan Zheng, Jianping Chen, Guangxu Ma, Abhay R Satoskar; Jiao L. Integrative genomic, proteomic and phenotypic studies of Leishmania donovani strains revealed genetic features associated with virulence and antimony-resistance, Parasites & Vectors, 2020, 13(1): 510.

4. Zhiwan Zheng, Jiao Li, Han Chen, Jinlei He, Qiwei Chen, Jianhui Zhang, Qi Zhou, DaliChen, Jianping Chen. Evaluation of in vitro antileishmanial efficacy of cyclosporin A and its non-immunosuppressive derivative, dihydrocyclosporin A, Parasites & Vectors, 2020, 13(1):94.

5. Jiao Li, Zhiwan Zheng, Gayathri Natarajan, Qiwei Chen, Dali Chen, Jianping Chen. The first successful report of the in vitro life cycle of Chinese Leishmania: the in vitro conversion of Leishmania amastigotes has been raised to 94% by testing 216 culture medium compound, Acta Parasitologica, 2017, 62(1): 154-163.（共一）